Artikel

Evidence vs. efficacy in allergen-speci c immunotherapy: Considerations using the example of tradable products in Germany

---

Abstract ‚e recently published S2k-guideline on (allergen-) specic immunotherapy (AIT) provides an excel-lent overview of the evidence on allergen prepara-tions available for AIT in Germany based on the published e„cacy studies. Publications based on the guideline are currently being used by the Ger-man associations of statutory health insurance physicians and German health insurance funds to open a discussion on the reimbursement status of allergen preparations. In our view, calling the re-imbursement status of perscribable and tradable AIT preparations into question on the basis of an assessment of the current body of evidence in the guideline is to be rigidly opposed. In Germany the Paul Ehrlich Institute (PEI) is the only authority empowered to decide on the marketability of AIT preparations, and decisions on the reimbursement status of AIT products need to be based on cost– benet analyses and not solely on an evaluation of the evidence. ‚e present article aims to examine the relationship between the evidence, e„cacy, tradability, and reimbursability of AIT prepara-tions.

---

Ketersediaan

Tidak ada salinan data

Informasi Detail

Judul Seri

-

No. Panggil

Artikel

Penerbit

German : Springer., 2016

Deskripsi Fisik

-

Bahasa

English

ISBN/ISSN

DOI: 10.1007/s40629-

Klasifikasi

NONE

Tipe Isi

-

Tipe Media

-

Tipe Pembawa

-

Edisi

Allergo J Int 2016; 25:38–43

Subjek

Medicine
Immunotherapy
Evidence
Efficacy

Info Detail Spesifik

-

Pernyataan Tanggungjawab

-

Versi lain/terkait

Lampiran Berkas

Komentar

---

Anda harus masuk sebelum memberikan komentar